Back to results
US 6,309,826 B1Granted
88kDa tumorigenic growth factor and antagonists
OwnerGinette Serreroinventor
Life of this patent
Estimating the term…
Abstract
This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
Claims36
A method for diagnosing tumorigenicity comprising the steps of:
- measuring the level of polynucleotide encoding human GP88 in tumorigenic tissue extracts or biological fluids;
- measuring the level of polynucleotide encoding human GP88 in corresponding normal or peripheral tissues;
- and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic tissue extracts or biological fluids is higher than the level in corresponding normal or peripheral tissues by an amount sufficient to indicate tumorigenicity.
A method for diagnosing tumorigenicity in human breast tissue comprising the steps of:
- measuring the level of mRNA encoding human GP88 in human tumorigenic breast tissue with a GP88 cDNA probe;
- measuring the level of polynucleotide encoding human GP88 in corresponding normal breast tissue;
- and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic human breast tissue is higher than the level in corresponding normal human breast tissue by an amount sufficient to indicate tumorigenicity.
A method for diagnosing tumorigenicity in human ovarian tissue comprising the steps of:
- measuring the level of mRNA encoding human GP88 in human tumorigenic ovarian tissue with a GP88 cDNA probe;
- measuring the level of polynucleotide encoding human GP88 in corresponding normal ovarian tissue;
- and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic ovarian breast tissue is higher than the level in corresponding normal human ovarian tissue by an amount sufficient to indicate tumorigenicity.
Dependencies are inferred from the claim text.